Prakash Chandra Jha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Prakash Chandra Jha has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Mohd Athar
Department of Physics, University of Cagliari, Cagliari, Italy
22 shared publications - Anu Manhas
Department of Chemistry, Pandit Deendayal Energy University, Gandhinagar, 382426, India
15 shared publications Hans Ågren
Royal Institute of Technology 1 Department of Theoretical Chemistry, School of Biotechnology SE-10691 Stockholm, Sweden
14 shared publicationsMohsin Y. Lone
Dept. of Chemistry, Indian Institute of Technology Gandhinagar, Gujarat, 382355, India
13 shared publicationsAnu Manhas
Department of Chemistry School of Energy Technology Pandit Deendayal Energy University Gandhinagar 382426 India
10 shared publications- Sivakumar Prasanth Kumar
Department of Immunology, St. Jude Children’s Research Hospital
7 shared publications
Latest Publications
- 26 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 8087-8104
Rational scaffold discovery for HIV-1 reverse transcriptase inhibitors via integrated in silico approaches
Human Immunodeficiency Virus-1 (HIV-1) Reverse Transcriptase (RT) remained an epicentre of therapeutic target, yet the efficacy of current non-nucleoside reverse transcriptase inhibitors (NNRTIs) is compromised by drug-induced liver toxicity. In this study, an integrated in silico approach combining similarity-based virtual screening, molecular docking, molecular dynamics, MM-PBSA, followed by molecular descriptor analysis, was employed to identify NNRTI scaffolds with improved safety and efficacy. The similarity-based virtual screening of ZINC and ChEMBL databases, followed by ADMET filtering, highlighted candidates with reduced predicted hepatotoxicity relative to FDA-approved NNRTIs. Among them, ZINC000066352010 exhibited a highly stable binding orientation within the NNRTI binding pocket, stabilized by hydrogen bonding with Lys101 and conserved hydrophobic contacts with Tyr181, Val179, and Trp229. Molecular Dynamics simulations provided compelling validation of this binding mode, as evidenced by the lowest ligand RMSD of 0.05 nm amongst the short-listed candidates, exhibited a persistent average number of hydrogen bonds of 1.95, and markedly reduced backbone fluctuations of RT relative to the apo-protein. These effects indicate enhanced conformational rigidity and long-term stability of the protein-ligand complex. The MM-PBSA provided quantitative thermodynamic support, with a binding energy of - 47.90 Kcal/mol, demonstrating stronger stabilization compared to the reference inhibitor (i.e., 9PJ). The enhanced affinity was driven predominantly by stable Van-der Waals interactions and minimized desolvation penalties. Frontier Molecular Orbital (FMO) and global reactivity descriptor analyses revealed an optimal HOMO-LUMO gap of 0.156 eV and an electrophilicity index of 0.14 eV, positioning it electronically within the window of FDA-approved NNRTIs, thereby indicating balanced reactivity and optimal electronic stability. Complementary electrostatic potential mapping highlighted well-defined reactive centres corroborative to the biomolecular target. Collectively, these findings positioned ZINC000066352010 as a promising NNRTI candidate with improved predicted safety and electronic stability parallel to an FDA-approved drug.
- 26 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 8087-8104
Rational scaffold discovery for HIV-1 reverse transcriptase inhibitors via integrated in silico approaches
Human Immunodeficiency Virus-1 (HIV-1) Reverse Transcriptase (RT) remained an epicentre of therapeutic target, yet the efficacy of current non-nucleoside reverse transcriptase inhibitors (NNRTIs) is compromised by drug-induced liver toxicity. In this study, an integrated in silico approach combining similarity-based virtual screening, molecular docking, molecular dynamics, MM-PBSA, followed by molecular descriptor analysis, was employed to identify NNRTI scaffolds with improved safety and efficacy. The similarity-based virtual screening of ZINC and ChEMBL databases, followed by ADMET filtering, highlighted candidates with reduced predicted hepatotoxicity relative to FDA-approved NNRTIs. Among them, ZINC000066352010 exhibited a highly stable binding orientation within the NNRTI binding pocket, stabilized by hydrogen bonding with Lys101 and conserved hydrophobic contacts with Tyr181, Val179, and Trp229. Molecular Dynamics simulations provided compelling validation of this binding mode, as evidenced by the lowest ligand RMSD of 0.05 nm amongst the short-listed candidates, exhibited a persistent average number of hydrogen bonds of 1.95, and markedly reduced backbone fluctuations of RT relative to the apo-protein. These effects indicate enhanced conformational rigidity and long-term stability of the protein-ligand complex. The MM-PBSA provided quantitative thermodynamic support, with a binding energy of - 47.90 Kcal/mol, demonstrating stronger stabilization compared to the reference inhibitor (i.e., 9PJ). The enhanced affinity was driven predominantly by stable Van-der Waals interactions and minimized desolvation penalties. Frontier Molecular Orbital (FMO) and global reactivity descriptor analyses revealed an optimal HOMO-LUMO gap of 0.156 eV and an electrophilicity index of 0.14 eV, positioning it electronically within the window of FDA-approved NNRTIs, thereby indicating balanced reactivity and optimal electronic stability. Complementary electrostatic potential mapping highlighted well-defined reactive centres corroborative to the biomolecular target. Collectively, these findings positioned ZINC000066352010 as a promising NNRTI candidate with improved predicted safety and electronic stability parallel to an FDA-approved drug.
- 22 January 2026
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 157 (2) , 251-261
Computational study of effect of progressive p-sulfonation at upper rim of calix[4]arene on adsorption with small gaseous molecule
- 22 January 2026
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 157 (2) , 251-261
Computational study of effect of progressive p-sulfonation at upper rim of calix[4]arene on adsorption with small gaseous molecule
- 14 January 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5719-5736
Structure-guided design and DFT-based optimization of natural product-derived dual inhibitors targeting CDK-1 and PARP-1
- 14 January 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5719-5736
Structure-guided design and DFT-based optimization of natural product-derived dual inhibitors targeting CDK-1 and PARP-1
- 2 May 2025
- Published by Wiley in Advanced Theory and Simulations
- Vol. 8 (10)
Investigation of Novel Cyclin‐Dependent Kinase 4 Inhibitors for Cancer Treatment: In Silico Approach Using Natural Product Libraries
Cancer remains a leading cause of mortality, often characterized by uncontrolled cell proliferation often driven by dysregulated cell cycle progression regulated by cyclin‐dependent kinases (CDKs). CDK4, a key regulator of the G1‐to‐S phase transition, is frequently overexpressed in various cancers. Inhibiting Cyclin Dependent Kinase 4 (CDK4) selectively offers a promising therapeutic strategy to induce cell cycle arrest. This study employed structure‐based pharmacophore modeling, molecular docking, molecular dynamics (MD) simulations, and Molecular Mechanics ‐ Poisson Boltzmann Surface area (MM‐PBSA) analysis to identify novel CDK4 inhibitors from natural product libraries. Two lead compounds, CAP03464597 and UKR1436403, displayed exceptional binding affinity and selectivity. Detailed interaction analyses revealed strong hydrogen bonding stabilizing ligand binding within the active site and hydrophobic interactions further reinforced ligand affinity. MD simulations confirmed the conformational stability of ligand‐bound complexes, with minimal fluctuations and sustained interactions throughout 300 ns simulations. Free energy decomposition pinpointed hotspot residues contributing significantly to binding affinity. These findings underscore the potential of computer‐aided drug discovery in identifying selective CDK4 inhibitors and highlight natural products as a valuable source for anticancer therapeutics. Furthermore, the promising in silico results suggest that CAP03464597 and UKR1436403 warrant further experimental validation, including biochemical assays and cellular studies, to establish their efficacy as potential CDK4‐targeted anticancer agents.
- 2 May 2025
- Published by Wiley in Advanced Theory and Simulations
- Vol. 8 (10)
Investigation of Novel Cyclin‐Dependent Kinase 4 Inhibitors for Cancer Treatment: In Silico Approach Using Natural Product Libraries
Cancer remains a leading cause of mortality, often characterized by uncontrolled cell proliferation often driven by dysregulated cell cycle progression regulated by cyclin‐dependent kinases (CDKs). CDK4, a key regulator of the G1‐to‐S phase transition, is frequently overexpressed in various cancers. Inhibiting Cyclin Dependent Kinase 4 (CDK4) selectively offers a promising therapeutic strategy to induce cell cycle arrest. This study employed structure‐based pharmacophore modeling, molecular docking, molecular dynamics (MD) simulations, and Molecular Mechanics ‐ Poisson Boltzmann Surface area (MM‐PBSA) analysis to identify novel CDK4 inhibitors from natural product libraries. Two lead compounds, CAP03464597 and UKR1436403, displayed exceptional binding affinity and selectivity. Detailed interaction analyses revealed strong hydrogen bonding stabilizing ligand binding within the active site and hydrophobic interactions further reinforced ligand affinity. MD simulations confirmed the conformational stability of ligand‐bound complexes, with minimal fluctuations and sustained interactions throughout 300 ns simulations. Free energy decomposition pinpointed hotspot residues contributing significantly to binding affinity. These findings underscore the potential of computer‐aided drug discovery in identifying selective CDK4 inhibitors and highlight natural products as a valuable source for anticancer therapeutics. Furthermore, the promising in silico results suggest that CAP03464597 and UKR1436403 warrant further experimental validation, including biochemical assays and cellular studies, to establish their efficacy as potential CDK4‐targeted anticancer agents.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 23 (2) , 85-98
Integrated Computational Analysis of C-2 Substituted Pyrazolopyrimidine and Amide Isosteres ALLINI: 3D-QSAR, Molecular Docking, and ADMET Studies
Introduction: The rapid increase in incidences of drug resistance and off-target toxicity in the case of Human Immunodeficiency Virus (HIV) has increased the demand for drugs with fewer side effects. HIV-1 Integrase (IN) is a promising target that helps integrate viral DNA with human DNA. It acts as a target for strand transfer inhibitors. However, the emergence of resistant mutations in the proteins necessitates the exploration of potent allosteric drugs. The allosteric integrase inhibitors (ALLINI) that interrupt the association of the integrase binding do-main of the lens epithelium growth factor (LEDGF/p75) and LEDGF/p75 binding site of the IN are more promising as they hinder site specificity and viral replication. Objective: In this study, a 3D-QSAR, molecular docking, and ADMET were carried out to investigate the binding of the C2-pyrazolopyrimidine amides and amide isosteres. Method: The 3D-QSAR model was developed using a series of 24 C-2 substituted pyrazolopyrimidine and amide isosteres. A statistically significant model was constructed, showing the determination coefficient (r2) and five-fold cross-validation (q2) at 0.946 and 0.506, respectively. Furthermore, the contour maps of the electrostatic potential and van der Waals coefficient provided structural modifications in the features to improve the inhibitory activity. Result: A molecular docking study was also performed to check the binding of the compounds to the LEDGF/p75 binding site of the IN, along with ADMET evaluation. Conclusion: The outcome of the study will help to prepare the potent molecules with enhanced allosteric inhibitory activity.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 23 (2) , 85-98
Integrated Computational Analysis of C-2 Substituted Pyrazolopyrimidine and Amide Isosteres ALLINI: 3D-QSAR, Molecular Docking, and ADMET Studies
Introduction: The rapid increase in incidences of drug resistance and off-target toxicity in the case of Human Immunodeficiency Virus (HIV) has increased the demand for drugs with fewer side effects. HIV-1 Integrase (IN) is a promising target that helps integrate viral DNA with human DNA. It acts as a target for strand transfer inhibitors. However, the emergence of resistant mutations in the proteins necessitates the exploration of potent allosteric drugs. The allosteric integrase inhibitors (ALLINI) that interrupt the association of the integrase binding do-main of the lens epithelium growth factor (LEDGF/p75) and LEDGF/p75 binding site of the IN are more promising as they hinder site specificity and viral replication. Objective: In this study, a 3D-QSAR, molecular docking, and ADMET were carried out to investigate the binding of the C2-pyrazolopyrimidine amides and amide isosteres. Method: The 3D-QSAR model was developed using a series of 24 C-2 substituted pyrazolopyrimidine and amide isosteres. A statistically significant model was constructed, showing the determination coefficient (r2) and five-fold cross-validation (q2) at 0.946 and 0.506, respectively. Furthermore, the contour maps of the electrostatic potential and van der Waals coefficient provided structural modifications in the features to improve the inhibitory activity. Result: A molecular docking study was also performed to check the binding of the compounds to the LEDGF/p75 binding site of the IN, along with ADMET evaluation. Conclusion: The outcome of the study will help to prepare the potent molecules with enhanced allosteric inhibitory activity.
- 23 January 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (6) , 5793-5809
Targeting cyclin-dependent kinase 11: a computational approach for natural anti-cancer compound discovery
Cancer, a leading global cause of death, presents considerable treatment challenges due to resistance to conventional therapies like chemotherapy and radiotherapy. Cyclin-dependent kinase 11 (CDK11), which plays a pivotal role in cell cycle regulation and transcription, is overexpressed in various cancers and is linked to poor prognosis. This study focused on identifying potential inhibitors of CDK11 using computational drug discovery methods. Techniques such as pharmacophore modeling, virtual screening, molecular docking, ADMET predictions, molecular dynamics simulations, and binding free energy analysis were applied to screen a large natural product database. Three pharmacophore models were validated, leading to the identification of several promising compounds with stronger binding affinities than the reference inhibitor. ADMET profiling indicated favorable drug-like properties, while molecular dynamics simulations confirmed the stability and favorable interactions of top candidates with CDK11. Binding free energy calculations further revealed that UNPD29888 exhibited the strongest binding affinity. In conclusion, the identified compound shows potential as a CDK11 inhibitor based on computational predictions, suggesting their future application in cancer treatment by targeting CDK11. These computational findings encourage further experimental validation as anti-cancer agents.
- 23 January 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (6) , 5793-5809
Targeting cyclin-dependent kinase 11: a computational approach for natural anti-cancer compound discovery
Cancer, a leading global cause of death, presents considerable treatment challenges due to resistance to conventional therapies like chemotherapy and radiotherapy. Cyclin-dependent kinase 11 (CDK11), which plays a pivotal role in cell cycle regulation and transcription, is overexpressed in various cancers and is linked to poor prognosis. This study focused on identifying potential inhibitors of CDK11 using computational drug discovery methods. Techniques such as pharmacophore modeling, virtual screening, molecular docking, ADMET predictions, molecular dynamics simulations, and binding free energy analysis were applied to screen a large natural product database. Three pharmacophore models were validated, leading to the identification of several promising compounds with stronger binding affinities than the reference inhibitor. ADMET profiling indicated favorable drug-like properties, while molecular dynamics simulations confirmed the stability and favorable interactions of top candidates with CDK11. Binding free energy calculations further revealed that UNPD29888 exhibited the strongest binding affinity. In conclusion, the identified compound shows potential as a CDK11 inhibitor based on computational predictions, suggesting their future application in cancer treatment by targeting CDK11. These computational findings encourage further experimental validation as anti-cancer agents.
- 24 December 2024
- Published by Springer Nature in Research on Chemical Intermediates
- Vol. 51 (2) , 789-809
Meglumine-catalyzed eco-friendly synthesis of pyrazolo[3,4-b]pyridines: exploring their potential against inflammation and arthritis using in silico studies
- 24 December 2024
- Published by Springer Nature in Research on Chemical Intermediates
- Vol. 51 (2) , 789-809
Meglumine-catalyzed eco-friendly synthesis of pyrazolo[3,4-b]pyridines: exploring their potential against inflammation and arthritis using in silico studies
- 11 November 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (43)
Development of Promising CDK5 Inhibitors Using Structure‐Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Approach
Cancer is highlighted as one of the deadliest diseases globally, with CDK5 identified as a key enzyme in cancer progression. Despite its potential as a therapeutic target, developing CDK5 inhibitors has been challenging. We used multicomplex‐based pharmacophore modeling on CDK5 complexes, identifying hydrophobic groups, hydrogen bond donors, and acceptors as crucial inhibition features. Validated models were used for the virtual screening of drug‐like natural product databases. Thereafter, the screened candidates were selected to study their binding pattern and binding efficiency in the enzyme. Four molecules were shortlisted and analyzed for electrostatic potential (ESP) energy maps. Molecular dynamic simulations and free energy calculations on the docked complexes revealed stable behavior for all, with three (CNP0299652, CNP0362830, and CNP0009633) showing higher Poisson Boltzmann surface area continuum solvation (MM‐PBSA) binding scores than the reference. These candidates demonstrated drug‐like characteristics, crucial amino acid interactions, favorable electron potentials in ESP plots, stable dynamicigher free energy, highlighting their potential as CDK5 inhibitors.
- 11 November 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (43)
Development of Promising CDK5 Inhibitors Using Structure‐Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Approach
Cancer is highlighted as one of the deadliest diseases globally, with CDK5 identified as a key enzyme in cancer progression. Despite its potential as a therapeutic target, developing CDK5 inhibitors has been challenging. We used multicomplex‐based pharmacophore modeling on CDK5 complexes, identifying hydrophobic groups, hydrogen bond donors, and acceptors as crucial inhibition features. Validated models were used for the virtual screening of drug‐like natural product databases. Thereafter, the screened candidates were selected to study their binding pattern and binding efficiency in the enzyme. Four molecules were shortlisted and analyzed for electrostatic potential (ESP) energy maps. Molecular dynamic simulations and free energy calculations on the docked complexes revealed stable behavior for all, with three (CNP0299652, CNP0362830, and CNP0009633) showing higher Poisson Boltzmann surface area continuum solvation (MM‐PBSA) binding scores than the reference. These candidates demonstrated drug‐like characteristics, crucial amino acid interactions, favorable electron potentials in ESP plots, stable dynamicigher free energy, highlighting their potential as CDK5 inhibitors.
- 8 November 2024
- Published by Springer Nature in Topics in Catalysis
- Vol. 68 (3-4) , 183-193
Theoretical Insights into the Anion Sensing Mechanism of Dicyanovinyl-Substituted Benzofurazan Through Intramolecular Charge Transfer (ICT)
- 8 November 2024
- Published by Springer Nature in Topics in Catalysis
- Vol. 68 (3-4) , 183-193
Theoretical Insights into the Anion Sensing Mechanism of Dicyanovinyl-Substituted Benzofurazan Through Intramolecular Charge Transfer (ICT)